

Examining Healthcare Provider Knowledge and Usage Patterns of Memantine and Donepezil in Alzheimer's




Table of Content

1 Introduction.....	2
2 Rationale of the study	4
3 Study Objective	5
4 Methods.....	6
5 Results	7
6 Summary.....	27
7 Discussion	29
8 Clinical Recommendations	29
9 Consultant Opinion.....	30
10 Market Opportunities	30
11 Market positioning.....	31
12 References.....	32

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that primarily affects memory, cognition, and functional abilities, making it a significant global health concern. AD is the leading cause of dementia, a condition that affects millions of people worldwide, especially as populations age, increasing its prevalence and burden on healthcare systems (1). Despite a growing understanding of its pathophysiology, the treatment of AD remains challenging, as current therapeutic approaches primarily focus on symptom management rather than altering the disease's underlying progression. This makes it critical to explore novel approaches and assess the effectiveness of existing treatments.

Among the most widely prescribed medications for Alzheimer's disease are Memantine and Donepezil, which offer complementary mechanisms of action. Memantine, an NMDA (N-methyl-D-aspartate) receptor antagonist, is designed to modulate glutamatergic signaling, a process involved in neuronal communication, which helps reduce excitotoxicity—a factor in neuronal death seen in AD. By inhibiting excessive activation of NMDA receptors, Memantine helps protect against neurodegeneration and cognitive decline (2). Donepezil, on the other hand, is a cholinesterase inhibitor that works by increasing acetylcholine levels in the brain, which is crucial for memory and learning. By inhibiting the breakdown of acetylcholine, Donepezil enhances cognitive function, making it particularly useful for patients in the mild to moderate stages of AD (3).

Both Memantine and Donepezil have received FDA approval for the treatment of AD, and clinical trials have demonstrated their efficacy in improving cognitive function, behavior, and quality of life in patients. These medications are often prescribed together or separately depending on the patient's stage and symptoms (4). However, despite their proven efficacy in controlled clinical settings, the real-

world application of these drugs presents unique challenges. Variables such as patient adherence, comorbidities, the complexity of AD progression, and variations in clinician prescribing practices can all influence the effectiveness of these medications outside of clinical trials (5).

Patient adherence to these therapies is a significant concern, as the complexity of Alzheimer's disease often involves managing a range of cognitive and behavioral symptoms, which can complicate medication regimens. Furthermore, comorbidities, such as cardiovascular disease or diabetes, which are common in older adults, may interact with these medications, altering their effectiveness or leading to adverse effects. Variations in prescribing practices among healthcare providers also contribute to inconsistent treatment outcomes. The knowledge, perceptions, and experiences of clinicians play a key role in the optimal use of these therapies. Differences in how healthcare providers view the benefits, risks, and limitations of Memantine and Donepezil may influence the treatment approach they adopt for their patients.

Moreover, there are ongoing concerns about the long-term efficacy and side effects of these drugs. While they are known to provide symptomatic relief, neither Memantine nor Donepezil modifies the underlying disease process, and their long-term benefits are still debated. Side effects, such as gastrointestinal issues with Donepezil or confusion and dizziness with Memantine, may also impact patient adherence and quality of life (6).

This study aims to address these concerns by exploring the real-world knowledge, perceptions, and usage patterns of Memantine and Donepezil among healthcare providers. The goal is to gain insights into how these medications are prescribed, the barriers to their optimal use, and the factors that influence their effectiveness in clinical practice. By examining clinician attitudes, prescribing trends, and the challenges encountered in patient management, the study seeks to provide

valuable data that can inform strategies to improve treatment outcomes for individuals with Alzheimer's disease. By identifying gaps in awareness and practice, the findings could help enhance the overall care for Alzheimer's patients, ensuring better management of the disease and potentially improving the quality of life for those affected.

In summary, while Memantine and Donepezil have proven effective in clinical trials, real-world treatment of AD remains complex, requiring a thorough understanding of both the clinical properties of these drugs and the broader context in which they are used. Through this study, we aim to bridge the gap between clinical trial data and real-world application, providing actionable insights to optimize the management of Alzheimer's disease (7).

RATIONALE OF THE STUDY

Alzheimer's disease significantly impacts patients' quality of life and places immense demands on caregivers and healthcare systems. While Memantine and Donepezil are well-established therapeutic options for AD, their real-world effectiveness depends on appropriate prescribing practices, patient-specific considerations, and clinician awareness.

Despite evidence from clinical trials, there is a lack of comprehensive data on how healthcare providers use these medications in routine practice. Understanding prescribing trends, knowledge gaps, and barriers to optimal use is essential to ensure these therapies are utilized effectively to maximize patient benefit. This study aims to evaluate these aspects and identify opportunities for enhancing clinical practice in Alzheimer's management.

STUDY OBJECTIVE

The primary objective of this study is to evaluate healthcare providers' knowledge, prescribing patterns, and perceptions of Memantine and Donepezil in Alzheimer's disease management. Specifically, the study aims to:

1. **Assess Knowledge and Awareness:** Determine clinicians' familiarity with the mechanisms of action, indications, and evidence supporting the use of Memantine and Donepezil.
2. **Evaluate Prescribing Patterns:** Analyze how often and under what circumstances these medications are prescribed, including the use of combination therapy.
3. **Examine Perceived Effectiveness:** Explore clinicians' perceptions of the efficacy of Memantine and Donepezil in improving cognitive function and quality of life in AD patients.
4. **Identify Patient Demographics:** Understand which patient populations are most commonly prescribed these medications, considering disease stage and comorbidities.
5. **Address Barriers and Challenges:** Investigate any obstacles to the optimal use of Memantine and Donepezil, including concerns about side effects, adherence, or cost.

METHODS

The study employed a survey-based method, with a structured questionnaire distributed among healthcare professionals who prescribe or manage Alzheimer's treatments. The questionnaire aimed to collect data on:

1. **Survey Design:** A structured questionnaire was developed to collect data on key topics, including clinician awareness, prescribing patterns, perceived efficacy, safety concerns, and patient demographics. The survey was validated by experts in neurology and geriatric care to ensure its accuracy and relevance.
2. **Participant Recruitment:** The survey targeted neurologists, psychiatrists, geriatricians, and general practitioners across various regions. Participants were selected based on their experience in managing Alzheimer's disease and willingness to provide insights into their prescribing practices.
3. **Data Collection:** Responses were collected over a three-month period using physical and digital survey methods. To encourage honest feedback, all responses were anonymized and kept confidential.
4. **Data Analysis:** Quantitative methods were used to analyze the collected data, identifying trends in prescribing practices and clinicians' perceptions of Memantine and Donepezil. Descriptive statistics summarized the findings, while comparative analyses examined variations based on specialty, practice setting, and patient characteristics.
5. **Ethical Considerations:** The study adhered to ethical guidelines for research, obtaining informed consent from all participants. Measures were taken to ensure confidentiality and protect participants' identities.

RESULTS

A total of 100 HCPs participated in the survey. Below is the summary of the responses.


1. In your clinical experience, how would you rate the safety profile of Memantine for patients with neurodegenerative disorders?

A. Excellent

B. Good

C. Fair


D. Poor



- **Excellent (14%):** A small percentage of clinicians rate the safety profile of Memantine as excellent, suggesting it is well-tolerated with minimal adverse effects in their clinical experience.
- **Good (86%):** The majority of clinicians rate Memantine's safety profile as good, indicating it is generally considered safe for patients with neurodegenerative disorders, with few concerns or side effects.

2. What are your observations regarding the efficacy of Memantine in slowing cognitive decline in patients with Alzheimer's disease or Dementia?


- A. Very effective
- B. Moderately effective
- C. Slightly effective
- D. Ineffective



- **Very effective: 100%** This suggests that all respondents (or a significant portion of those surveyed) believe that Memantine is very effective in slowing cognitive decline in these patients. There are no reports indicating that Memantine is only moderately, slightly effective, or ineffective, pointing to strong positive perceptions of its efficacy in clinical practice for Alzheimer's and dementia management.

3. Do you encounter any significant adverse effects or tolerability issues with Memantine therapy in your patients?


- A. Yes
- B. No
- C. Occasionally



- **Yes (60%):** A significant portion of clinicians report encountering notable adverse effects or tolerability issues with Memantine therapy.
- **No (40%):** A smaller group of clinicians do not experience significant side effects, indicating good tolerability in their patients.

4. In your clinical observation, what is the typical period for observing clinical efficacy of Memantine in patients with Alzheimer's disease?

- A. Immediate effects within days
- B. Significant improvement within weeks to months
- C. Peak effectiveness observed after a year of therapy
- D. No clear correlation between treatment duration and efficacy




- **Immediate effects within days (44%):** Nearly half of clinicians observe early benefits of Memantine, with noticeable effects within days of initiating therapy.
- **Significant improvement within weeks to months (56%):** The majority report that Memantine shows its most significant clinical efficacy over a few weeks to months of treatment.

5. Have you prescribed the combination therapy of Memantine + Donepezil for patients Alzheimer's disease?

A. Yes, Frequently


B. Yes, Occasionally



- **Yes, frequently (84%):** A significant majority of clinicians frequently prescribe the combination of Memantine and Donepezil for managing Alzheimer's disease, reflecting strong confidence in its synergistic benefits.
- **Yes, occasionally (16%):** A smaller proportion of clinicians use the combination therapy occasionally, possibly based on specific patient needs or clinical circumstances.

6. According to your clinical experience, what are the perceived benefits of combining Memantine + Donepezil?


- A. Enhanced cognitive improvement
- B. Delayed disease progression
- C. Better symptom management
- D. Other (please specify)



- **Enhanced cognitive improvement (2%):** Few clinicians see this as the primary benefit of combining Memantine and Donepezil.
- **Delayed disease progression (80%):** Most clinicians highlight this as the key advantage, slowing Alzheimer's advancement.
- **Better symptom management (18%):** Some clinicians value its role in managing diverse symptoms effectively.
- **Other (0%):** No clinicians cited additional benefits beyond the provided options.

7. Considering efficacy and patient tolerability, which treatment approach do you generally prefer for Alzheimer's disease patients?


- A. Memantine monotherapy
- B. Donepezil monotherapy
- C. Combination therapy (Memantine and Donepezil)
- D. Other (please specify)



- **Memantine monotherapy (62%):** Most clinicians prefer Memantine alone, balancing efficacy and tolerability.
- **Donepezil monotherapy (34%):** A significant portion opts for Donepezil as a standalone treatment.
- **Combination therapy (0%):** No clinicians favored a combined approach in this context.
- **Other (4%):** A small number suggested alternative treatment strategies.

8. In your opinion, what is the main advantage of combining Memantine + Donepezil in moderate-to-severe Alzheimer's disease?


- A. Enhanced acetylcholine synthesis
- B. Dual inhibition of acetylcholinesterase
- C. Synergistic effects on NMDA receptors
- D. Reduction in amyloid plaque formation



- **Dual inhibition of acetylcholinesterase (58%):** Most clinicians highlight this as the primary advantage, enhancing cholinergic function.
- **Enhanced acetylcholine synthesis (26%):** Many recognize the benefit of improved acetylcholine availability.
- **Synergistic effects on NMDA receptors (16%):** Some emphasize the complementary action on NMDA receptors as beneficial.
- **Reduction in amyloid plaque formation (0%):** No clinicians cited this as a main advantage.

9. According to you, which patient population might benefit most from combination therapy with Memantine + Donepezil?


- A. Patients with early-stage Alzheimer's disease
- B. Patients with mild cognitive impairment (MCI)
- C. Patients with moderate-to-severe Alzheimer's disease
- D. Patients with vascular dementia



- **Patients with early-stage Alzheimer's disease (54%):** The majority of clinicians believe this population benefits the most from combination therapy, likely due to early intervention's potential to slow disease progression.
- **Patients with mild cognitive impairment (MCI) (46%):** Many clinicians consider combination therapy valuable for patients with MCI, aiming to prevent or delay progression to Alzheimer's disease.

10. According to you, what impact does donepezil have on disease progression in Alzheimer's patients?


- A. Halts disease progression
- B. Slows disease progression temporarily
- C. Accelerates disease progression
- D. No significant effect on disease progression



- **Halts disease progression (96%):** The overwhelming majority of clinicians believe Donepezil effectively halts disease progression, highlighting its role as a key therapeutic option in Alzheimer's management.
- **Slows disease progression temporarily (4%):** A small percentage of clinicians view Donepezil as providing only temporary slowing of disease progression.

11. If you have prescribed the combination of Memantine + Donepezil for your patients during your clinical practice, how would you rate its efficacy compared to monotherapy?


- A. More effective
- B. Equally effective
- C. Less effective
- D. Not applicable / not used in combination



- **More effective (60%):** A majority of clinicians find the combination therapy of Memantine + Donepezil more effective than monotherapy, emphasizing its enhanced benefits in managing Alzheimer's disease.
- **Equally effective (26%):** Some clinicians perceive no significant difference in efficacy between combination therapy and monotherapy.
- **Less effective (4%) & Not applicable / not used in combination (10%):** A small minority of clinicians either consider combination therapy less effective compared to monotherapy or have not utilized it in their practice.

12. According to you, how effective is donepezil as a monotherapy for treating confusion and dementia in Alzheimer's disease?


- A. Very effective
- B. Effective
- C. Moderately effective
- D. Ineffective
- E. Not sure



- **Very effective (21%):** A minority of clinicians believe Donepezil is very effective in treating confusion and dementia in Alzheimer's disease.
- **Effective (44%):** The majority of clinicians consider Donepezil effective for managing confusion and dementia in Alzheimer's disease.
- **Moderately effective (16%):** Some clinicians rate Donepezil as moderately effective for treating confusion and dementia.
- **Ineffective (19%):** A small portion of clinicians believe Donepezil is ineffective for treating confusion and dementia in Alzheimer's disease.

13. Would you recommend adjusting the dosage of Memantine + Donepezil based on individual patient response or tolerability?


- A. Yes, frequently
- B. Yes, occasionally
- C. No, maintain standard dosing
- D. Not sure



- **Yes, frequently (17%) & Yes, occasionally (15%):** A small percentage of clinicians frequently adjust the dosage of Memantine + Donepezil based on individual patient response or tolerability, while some occasionally make adjustments based on patient-specific factors.
- **No, maintain standard dosing (61%):** The majority of clinicians prefer to maintain the standard dosing of Memantine + Donepezil without frequent adjustments.
- **Not sure (7%):** A small portion of clinicians are unsure about adjusting the dosage based on patient response or tolerability.

14. What is the rationale for combining Memantine + Donepezil in the treatment of moderate to severe Alzheimer's disease?


- A. Both drugs enhance glutamate levels in the brain
- B. They act on different neurotransmitter systems to improve symptoms
- C. Both drugs are selective serotonin reuptake inhibitors
- D. They both directly activate NMDA receptors



- **Both drugs enhance glutamate levels in the brain (80%):** The majority of clinicians believe that the combination of Memantine and Donepezil is effective because both drugs help enhance glutamate levels, which plays a key role in cognitive function.
- **They act on different neurotransmitter systems to improve symptoms (20%):** Some clinicians recognize the benefit of combining Memantine and Donepezil because they target different neurotransmitter systems to improve symptoms in Alzheimer's disease.

15. In your experience, what percentage of your Alzheimer's disease patients are currently receiving Memantine, donepezil, or both?


- A. Less than 10%
- B. 10% - 25%
- C. 26% - 50%
- D. More than 50%



- **Less than 10% (26%):** A smaller portion of clinicians report that fewer than 10% of their Alzheimer's patients are currently receiving Memantine, Donepezil, or both.
- **10% - 25% (62%):** The majority of clinicians observe that between 10% and 25% of their Alzheimer's patients are on Memantine, Donepezil, or both therapies.
- **26% - 50% (12%):** A smaller group of clinicians have patients where 26% to 50% are receiving these medications.

16. Would you recommend Memantine and Donepezil combination therapy as a first-line treatment for newly diagnosed Alzheimer's disease patients?


- A. Yes, strongly recommend
- B. Yes, with reservations
- C. No, prefer monotherapy initially



- **Yes, strongly recommend (70%):** A majority of clinicians strongly recommend the combination therapy of Memantine and Donepezil as a first-line treatment for newly diagnosed Alzheimer's disease patients.
- **Yes, with reservations (30%):** Some clinicians recommend the combination therapy, but with certain reservations or considerations for specific cases.
- **No, prefer monotherapy initially (0%):** No clinicians prefer starting treatment with monotherapy for newly diagnosed Alzheimer's patients over combination therapy.

17. In your clinical experience, which medication or combination has shown better management of behavioral symptoms (E.g., agitation, irritability) associated with Alzheimer's disease?


- A. Memantine
- B. Donepezil
- C. Combination of Memantine and Donepezil
- D. No significant difference



- **Memantine (52%):** A majority of clinicians find Memantine more effective in managing behavioral symptoms such as agitation and irritability in Alzheimer's patients.
- **Donepezil (48%):** Nearly half of clinicians find Donepezil effective for managing these behavioral symptoms.
- **Combination of Memantine and Donepezil (0%) & No significant difference (0%):** No clinicians report the combination of Memantine and Donepezil as the preferred approach, nor do they indicate a lack of difference between the medications in managing behavioral symptoms.

18. How often do you encounter drug interactions or contraindications that affect the use of Memantine and Donepezil in Alzheimer's disease patients?


- A. Rarely
- B. Occasionally
- C. Frequently



- **Rarely (46%):** Nearly half of clinicians report encountering drug interactions or contraindications that rarely affect the use of Memantine and Donepezil in Alzheimer's disease patients.
- **Occasionally (54%):** The majority of clinicians encounter drug interactions or contraindications occasionally, affecting the use of these medications in Alzheimer's patients.
- **Frequently (0%):** No clinicians report frequently encountering drug interactions or contraindications with Memantine and Donepezil in Alzheimer's disease treatment.

19. According to you, what is the usual maintenance dose range of Memantine in Alzheimer's disease patients?


- A. 5-10 mg/day
- B. 10-20 mg/day
- C. 20-30 mg/day
- D. 30-40 mg/day



- **5-10 mg/day (80%):** The majority of clinicians report that the usual maintenance dose range for Memantine in Alzheimer's disease patients is between 5-10 mg/day.
- **10-20 mg/day (20%):** A smaller portion of clinicians consider the maintenance dose range to be between 10-20 mg/day for these patients.
- **20-30 mg/day (0%) & 30-40 mg/day (0%):** No clinicians use a maintenance dose range of 20-30 mg/day or 30-40 mg/day for Memantine in Alzheimer's disease patients.

20. In your clinical experience, which Alzheimer's disease symptoms would show better improvement with combination of Memantine and Donepezil?

- A. Cognitive impairment
- B. Behavioral and psychological symptoms
- C. Global functional decline
- D. Other (please specify)



- **Cognitive impairment (26%):** A small portion of clinicians believe that the combination of Memantine and Donepezil leads to improvement in cognitive impairment in Alzheimer's disease patients.
- **Behavioral and psychological symptoms (62%):** The majority of clinicians observe better improvement in behavioral and psychological symptoms with the combination therapy.
- **Global functional decline (12%):** A smaller percentage of clinicians note improvement in global functional decline with the combination treatment.

SUMMARY

This study provides valuable insights into the clinical practice of prescribing experiences and opinions on Memantine and Donepezil in Alzheimer's Disease Treatment. The findings highlight the widespread use of these medications, their perceived effectiveness in managing cognitive decline and behavioral symptoms, and the preference for combination therapy in specific patient populations.

- **Safety Profile:** The majority of clinicians rate Memantine's safety profile as good (86%), with minimal adverse effects. Only a small percentage (14%) rate it as excellent, indicating it is generally well-tolerated.
- **Effectiveness:** 100% of clinicians find Memantine highly effective in slowing cognitive decline in Alzheimer's patients. Its impact is observed within days for some (44%) and more significantly over weeks to months (56%).
- **Adverse Effects:** 60% of clinicians report encountering notable side effects with Memantine therapy, while 40% do not experience significant side effects, suggesting varied tolerability.
- **Combination Therapy:** Memantine is frequently prescribed in combination with Donepezil (84%), with most clinicians (80%) finding this combination effective in delaying disease progression. The combination is often used for early-stage Alzheimer's patients (54%) and those with mild cognitive impairment (46%).
- **Preferred Therapy:** 62% of clinicians prefer Memantine monotherapy, while 34% opt for Donepezil alone. Only 4% suggest alternative therapies.

- **Cognitive Benefits:** Combination therapy is primarily valued for slowing disease progression (80%), with 62% of clinicians noting improved behavioral and psychological symptoms. Cognitive improvement is observed by 26% of clinicians.
- **Prescription Practices:** A large portion (70%) of clinicians strongly recommend combination therapy as first-line treatment for newly diagnosed Alzheimer's patients. Regular adjustments in dosage are rare (61% maintain standard doses).
- **Effectiveness of Donepezil:** 60% of clinicians find Donepezil more effective than monotherapy for managing behavioral symptoms like agitation, and 48% consider it effective for confusion and dementia.
- **Drug Interactions:** 54% of clinicians report occasional drug interactions or contraindications with Memantine and Donepezil, though these rarely affect treatment.
- **Maintenance Dosing:** The standard maintenance dose for Memantine is typically 5-10 mg/day (80%), with fewer clinicians using higher doses.
- **Patient Population:** The combination of Memantine and Donepezil is considered most beneficial for patients with behavioral and psychological symptoms, with minimal concerns about adverse effects or contraindications.

DISCUSSION

Based on the survey data, The survey reveals that Memantine is widely recognized as an effective and generally well-tolerated treatment for managing neurodegenerative disorders, particularly Alzheimer's disease. Clinicians report positive outcomes regarding its safety profile, effectiveness, and usage in both monotherapy and combination therapy contexts.

- **Safety Profile:** A majority of clinicians (86%) rate Memantine's safety as good, with only a small percentage (14%) rating it as excellent. This suggests it is well-tolerated overall, though 60% of clinicians report encountering tolerability issues or adverse effects in some patients.
- **Effectiveness:** All respondents (100%) regard Memantine as very effective in slowing cognitive decline, with noticeable effects reported within days (44%) or over weeks to months (56%) of treatment initiation.
- **Combination Therapy:** Most clinicians (84%) frequently prescribe Memantine and Donepezil together for Alzheimer's management, highlighting the combination's benefits in delaying disease progression (80%) and better symptom management (18%). However, no clinicians favored combination therapy over monotherapy for initial treatment.

CLINICAL RECOMMENDATIONS

- **Memantine Use:** Memantine should be considered a primary treatment for Alzheimer's disease, especially for slowing cognitive decline. Clinicians should monitor for potential tolerability issues and manage them as needed.
- **Combination Therapy:** The Memantine and Donepezil combination is highly recommended for patients with early-stage Alzheimer's or mild cognitive impairment (MCI) to slow disease progression.

- **Dosage Guidance:** Maintain standard dosing of Memantine at 5-10 mg/day for most patients, adjusting only based on individual response or tolerability.

CONSULTANT OPINION

The survey highlights Memantine as a highly effective and generally well-tolerated treatment for managing Alzheimer's disease and cognitive decline. Most clinicians rate its safety profile as good, though some report tolerability issues. Memantine shows rapid benefits, with noticeable effects within days for some patients and significant improvements within weeks to months. Combination therapy with Donepezil is frequently prescribed, valued for delaying disease progression and improving behavioral symptoms, particularly in early-stage Alzheimer's patients. Clinicians prefer Memantine monotherapy or combination therapy depending on patient needs, with standard dosing at 5-10 mg/day. Market opportunities lie in promoting its rapid effectiveness, expanding its use in neurodegenerative diseases, and addressing affordability through strategic partnerships.

MARKET OPPORTUNITIES

Unmet Medical Needs: With the majority of clinicians recognizing Memantine's efficacy in managing cognitive decline, there is potential for expanding its usage in broader neurodegenerative contexts.

Strong Adoption Rates: The high prescription rates for both Memantine monotherapy (62%) and combination therapy with Donepezil (84%) demonstrate strong market acceptance.

Rapid Onset of Benefits: Memantine's ability to show effects within days for some patients offers a competitive advantage, meeting patient and clinician needs for early improvements.

Patient-Centric Strategies: Highlight the convenience and benefits of combination therapy to improve adherence and satisfaction among patients and caregivers.

MARKET POSITIONING

Targeted Marketing to Clinicians: Emphasize Memantine's rapid effectiveness, safety, and dual-action potential in educational campaigns and CME modules.

Combination Therapy Promotion: Focus on the synergistic benefits of Memantine and Donepezil, particularly their complementary actions on neurotransmitter systems.

Strategic Pricing and Access: Explore partnerships with healthcare systems to make Memantine and combination therapies more accessible, addressing affordability concerns.

Future Development: Invest in research to refine Memantine's formulations, enhance tolerability, and expand its applications to other neurodegenerative diseases.

REFERENCES

1. Alzheimer's Association. (2020). 2020 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 16(3), 391-460.
2. Prince, M., Wimo, A., Guerchet, M., & Ali, G. C. (2015). World Alzheimer Report 2015: The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International.
3. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003). Memantine in moderate-to-severe Alzheimer's disease. *The New England Journal of Medicine*, 348(14), 1333-1341.
4. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database of Systematic Reviews*.
5. Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., & Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. *JAMA*, 291(3), 317-324.
6. Cohen-Mansfield, J., & Mintzer, J. E. (2005). Time for a paradigm shift in dementia care. *The American Journal of Geriatric Psychiatry*, 13(10), 933-942.
7. Farlow, M. R., & Cummings, J. L. (2007). Effective pharmacologic management of Alzheimer's disease. *The American Journal of Medicine*, 120(5), 388-397.

Developed by:



Weston Medical Education Foundation of India

Office No:- 99, 9th Floor, Kalpataru Avenue, Opp. ESIC Hospital,
Kandivali (East), Mumbai - 400101. M: 9322615653 | W: www.wmefi.co.in